Skip to content
Baret News – Lifestyle
Author:
Gain Therapeutics, Inc.
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
November 5, 2026
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
October 8, 2026
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
October 1, 2026
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
September 29, 2026
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
September 17, 2026
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
August 25, 2026
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
August 11, 2026
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
July 16, 2026
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
June 29, 2026
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 10, 2026
1
2
Next Page
→